Jennison Associates’s Amicus Therapeutics FOLD Stock Holding History

Jennison Associates’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-240,000	Closed	-$5.54M	–	693
2020 Q4	$5.54M	Buy	+240,000	New	+$4.91M	﹤0.01%	450

Other funds holding FOLD

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Jennison Associates's FOLD Position: Q3 2022 in Review

Jennison Associates sold out of Amicus Therapeutics (FOLD) in Q3 2022, closing a stake of 65,788 shares — an estimated $707K sold.

Jennison Associates first reported a position in FOLD in Q2 2015 and held it in 29 quarters. The position peaked at $158M in Q2 2018. 222 funds tracked by Wall St. Rank hold FOLD as of Q3 2022.

Jennison Associates reported no remaining Amicus Therapeutics position as of Q3 2022 after selling out during the quarter.
Jennison Associates sold 65,788 Amicus Therapeutics shares in Q3 2022, an estimated $707K.
Jennison Associates first reported a position in Amicus Therapeutics in Q2 2015 and held it in 29 quarters.
Jennison Associates's Amicus Therapeutics position peaked at $158M in Q2 2018.
222 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q3 2022.

Based on Jennison Associates's 13F filing for Q3 2022, filed 1 Nov 2022.